Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Placebo Controlled, Repeat-dose, Cross-over Phase I Study to Evaluate the Pro-arrhythmic Potential of GSK3039294 in Healthy Participants

Trial Profile

A Randomised, Double-blind, Placebo Controlled, Repeat-dose, Cross-over Phase I Study to Evaluate the Pro-arrhythmic Potential of GSK3039294 in Healthy Participants

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs GSK 3039294 (Primary)
  • Indications Amyloidosis
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Oct 2018 Planned End Date changed from 2 May 2019 to 3 May 2019.
    • 05 Oct 2018 Planned primary completion date changed from 2 May 2019 to 3 May 2019.
    • 05 Oct 2018 Planned initiation date changed from 11 Jul 2018 to 12 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top